The first meeting of the National Academy of Medicine Committee on Temporomandibular Disorders (TMD): From Research Discoveries to Clinical Treatment will be held Tuesday, January 29, 2019 at the National Academy of Sciences building in Washington, D.C.&
The Trial of the Class Action brought by Canadian patients who were implanted with Vitek Proplast TMJ implants, against Health Canada, alleging negligent regulation starts on April 1, 2019 in Toronto.
The following article by Roger B. Fillingim, Gary D. Slade, Joel D. Greenspan, Ronald Dubner, William Maixner, Eric Bair, and Richard Ohrbach was published in the journal of Pain, November 2018. We are grateful to Dr. Fillingim for writing the following
We want you to be among the first to know that because of the advocacy efforts of The TMJ Association, the National Academy of Medicine (NAM) will conduct a first-ever study on Temporomandibular Disorders (TMD).
Fear of the dentist is practically a rite of passage in youth. Growing up, I wasn't exactly afraid of the dentist; rather, any excuse to leave school early was a powerful incentive. These days, I have a more complicated relationship with dentistry: I go to get answers and try to feel better, but I always pop a prophylactic ibuprofen or two in case my jaw protests from the oral gymnastics.
Are you a woman with "TMJ" pain in facial muscles, who has either:
a. recently had Botox© injections for your pain or
b. not had Botox© for your pain but has thought about such treatment?
If either is true for you, you may qualify for an observational research study centrally administered by the NYU College of Dentistry. It is funded by the National Institutes of Health (NIH). The purpose of this study is to understand potential health risks that may be caused by treating "TMJ pain" with Botox© injections.
It is still all too fresh in the minds of many patients. Fifty years ago, between the 1970s and 1980s, some 10,000 TMJ patients received Vitek jaw implant devices.
The NIH Common Fund's Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain.
FDA Public Meeting on Patient-Focused Drug Development for Chronic Pain
On July 9, 2018, FDA hosted a public meeting on Patient-Focused Drug Development for Chronic Pain. https://www.federalregister.gov/documents/2018/05/15/2018-10284/patient-focused-
We were recently contacted by Tom P. who informed us that he was including The TMJ Association (TMJA), in his financial planning. Tom wrote the following for us to share with our readers: